[Federal Register: September 29, 2008 (Volume 73, Number 189)]
[Notices]               
[Page 56612]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29se08-105]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated May 19, 2008 and published in the Federal Register 
on May 27, 2008 (73 FR 30418), AMRI Rensselaer, Inc., 33 Riverside 
Avenue, Rensselaer, New York 12144, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)............................  I
Tetrahydrocannabinols (7370)................  I
Amphetamine (1100)..........................  II
Lisdexamfetamine (1205).....................  II
Methylphenidate (1724)......................  II
Pentobarbital (2270)........................  II
Hydrocodone (9193)..........................  II
Meperidine (9230)...........................  II
Dextropropoxyphene, bulk (non-dosage form)    II
 (9273).
Oxymorphone (9652)..........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The company plans to manufacture bulk controlled substances for use 
in product development and for distribution to its customers. In 
reference to drug code 7360 (Marihuana), the company plans to bulk 
manufacture cannabidiol as a synthetic intermediate. This controlled 
substance will be further synthesized to bulk manufacture a synthetic 
THC (7370). No other activity for this drug code is authorized for this 
registration.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
AMRI Rensselaer, Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated AMRI Rensselaer, Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

     Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-22876 Filed 9-26-08; 8:45 am]

BILLING CODE 4410-09-P